Multiple molecular pathways have been examined as potential therapeutic targets for respiratory disease. In order to target these pathways, several biologics have been developed. Biologics are defined as any treatment that is synthesized from a biological source. These class of drugs include vaccines, antigens, recombinant DNA, and antibodies. Much progress has been made in identifying key pathways and molecules associated with the development and maintenance of respiratory diseases. As such, there is presently a strong drive to translate our knowledge of the pathogenesis of respiratory disease into biologics that ameliorate clinical symptoms. The current Frontiers Research Topic is to summarize translational research of emerging biologics that target immunological pathways in respiratory disease. Contributions may include reviews and original articles in the relevant field of respiratory physiology and immunology. Clinical studies that focus on novel aspects of a disease that may represent a new therapeutic target are also welcome.
Multiple molecular pathways have been examined as potential therapeutic targets for respiratory disease. In order to target these pathways, several biologics have been developed. Biologics are defined as any treatment that is synthesized from a biological source. These class of drugs include vaccines, antigens, recombinant DNA, and antibodies. Much progress has been made in identifying key pathways and molecules associated with the development and maintenance of respiratory diseases. As such, there is presently a strong drive to translate our knowledge of the pathogenesis of respiratory disease into biologics that ameliorate clinical symptoms. The current Frontiers Research Topic is to summarize translational research of emerging biologics that target immunological pathways in respiratory disease. Contributions may include reviews and original articles in the relevant field of respiratory physiology and immunology. Clinical studies that focus on novel aspects of a disease that may represent a new therapeutic target are also welcome.
